STOCK TITAN

Catalent Inc. - CTLT STOCK NEWS

Welcome to our dedicated news page for Catalent (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalent's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalent's position in the market.

Rhea-AI Summary
ViroCell Biologics appoints Traci Kyes as VP of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe) to drive growth in respective regions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary
Catalent, Inc. appoints David McErlane as Group President of Biologics segment, expecting positive impact on business growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
management
-
Rhea-AI Summary
Catalent, Inc. receives notice of non-compliance with NYSE listing requirements due to delayed filing of Annual Report on Form 10-K. Company has six months to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
Rhea-AI Summary
Catalent, Inc. executives to present at investor conferences on September 12 and 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
-
Rhea-AI Summary
Catalent announces appointment of four new independent directors and the establishment of a new Strategic and Operational Review Committee. John Greisch appointed as Executive Chair. Enters into Cooperation Agreement with Elliott Investment Management L.P.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
none
-
Rhea-AI Summary
Catalent Inc. reports Q4'23 net revenue of $1.07 billion, a decrease of 17% compared to Q4'22. Q4'23 net loss of $(86) million. Adjusted EBITDA for Q4'23 decreased 61% to $139 million. Fiscal 2023 net revenue decreased 11% to $4.28 billion. FY'24 financial guidance includes net revenue of $4.3 billion to $4.5 billion and Adjusted EBITDA of $680 million to $760 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
Rhea-AI Summary
Catalent, Inc. to release Q4 2023 financial results on August 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
-
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) appoints Lisa Evoli as Senior Vice President & Chief Human Resources Officer, bringing over 25 years of experience from Integra Lifesciences, TE Connectivity, Johnson & Johnson, and Motorola. She will lead global HR strategy, talent acquisition, leadership development, diversity and inclusion, organizational design, compensation and benefits, HR operations and technology, and performance management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.01%
Tags
none
Catalent Inc.

NYSE:CTLT

CTLT Rankings

CTLT Stock Data

10.18B
179.72M
0.49%
111.38%
4.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Somerset

About CTLT

catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p